Intellia Therapeutics

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$6.50-$28.18
Market Cap
$755.6M
Shares Short
26M

Financials

See more
Revenue (12 Mos)
$57.8M
Revenue Growth (YoY)
-24%
Gross Profit (12 Mos)
-$408.4M
Diluted EPS
-$5.25

News

See more

Yahoo Finance • 16 hours ago

Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion

Yahoo Finance • 16 hours ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Yahoo Finance • 19 hours ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Yahoo Finance • yesterday

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

About

CEO
Dr. John M. Leonard M.D.
Address
40 Erie Street, Cambridge, MA, United States, 02139
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
403